Literature DB >> 10433549

Optimal peritoneal dialysis for patients from Hong Kong.

K N Lai1, W K Lo.   

Abstract

The socioeconomic statuses of Asian countries are diverse and government reimbursement policies for renal replacement programs vary greatly from one country to another. Both factors affect not only the availability of treatment but also the choice of dialysis modality. Despite the economic growth of Hong Kong over the past three decades, the resources spent by our government on health services are less than other developed countries. The National Health Service, which is run on a tight budget, supports almost 95% of the patients on renal replacement programs. Due to the cost-effectiveness and reimbursement from the government, 79% of patients with end-stage renal failure in Hong Kong are treated with continuous ambulatory peritoneal dialysis (CAPD). All new patients entering the renal replacement program run by the National Health Service are offered CAPD as the first-line dialytic treatment. Due to budgetary constraint, over the past 10 years dialysis centers in Hong Kong have adopted a small-volume regime of 3 x 2-L daily exchanges as the initial dialysis prescription. This dialysis prescription will be considered to be suboptimal by Western standards, but the survival of these patients was comparable to, or even better than, other areas despite a lower Kt/V. These preliminary studies suggest small-volume dialysis may be an acceptable compromise in Asian populations with their smaller body size, given the financial constraints. These issues are especially important in Asia, where financial resources for renal replacement therapy are still limited in most countries and many patients have to continue working to pay for their renal replacement treatment. Using this small-volume dialytic regime, more patients may be treated with the limited financial resources. Furthermore, our experience raises the question of the importance of nutritional status in patient survival.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433549

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  4 in total

1.  A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.

Authors:  Kar Neng Lai; Man Fai Lam; Joseph C K Leung; Loretta Y Chan; Christopher W K Lam; Iris H S Chan; Hoi Wong Chan; Chun Sang Li; Sunny S H Wong; Yiu Wing Ho; Au Cheuk; Matthew K L Tong; Sydney C W Tang
Journal:  Perit Dial Int       Date:  2011-11-03       Impact factor: 1.756

2.  Long-term efficacy of intermittent peritoneal dialysis using various doses.

Authors:  Zhi-Yong Zhang; Chun-Hua Zhou; Ming-Xu Li; Yong-Wu Yu
Journal:  Exp Ther Med       Date:  2011-12-30       Impact factor: 2.447

Review 3.  Incremental Versus Standard (Full-Dose) Peritoneal Dialysis.

Authors:  Melissa S Cheetham; Yeoungjee Cho; Rathika Krishnasamy; Arsh K Jain; Neil Boudville; David W Johnson; Louis L Huang
Journal:  Kidney Int Rep       Date:  2021-12-01

Review 4.  Peritoneal dialysis: the ideal bridge from conservative therapy to kidney transplant.

Authors:  Sydney C W Tang; Kar Neng Lai
Journal:  J Nephrol       Date:  2020-07-11       Impact factor: 3.902

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.